Efficacy of Jinshuibao as an adjuvant treatment for chronic renal failure in China: A meta-analysis

Abstract

Background: Research on Jinshuibao (JSB) for chronic renal failure (CRF) is limited, its clinical efficacy on CRF has not been evaluated. Our aim is to systematically evaluate the efficacy of JSB for the treatment of CRF in Chinese patients, and to provide evidence-based medical advice for clinical practice. Methods: Randomized controlled trials (RCTs) which compared JSB combined with conventional treatment (CT) with CT alone in CRF were searched in 8 databases including PubMed, EMBASE, Cochrane Library, Web of science, China Biology Medicine disc, Wanfang, Chinese Scientific Journal Database (VIP) and China National Knowledge Infrastructure form inception to March 31, 2023. RevMan5.4 statistical software was used for meta-analysis. Results: 17 trials involving 1431 cases were identified for meta-analysis. The results showed that total effective rate (relative risk [RR] = 1.25, 95% confidence internal [CI]: 1.17–1.34, P < .00001), creatinine clearance rate (Ccr) (MD = −8.63, 95% CI: −12.42 to −4.84, P < .00001), albumin (Alb) (MD = −2.88, 95% CI: −4.85 to −0.92, P = .004) and hemoglobin (Hb) (MD = −5.88, 95% CI: −7.42 to −4.34, P < .00001) in JSB plus CT were significantly higher than those in CT; while blood urea nitrogen (BUN) (MD = 2.03, 95% CI: 1.27–2.80, P < .00001), serum creatinine (Scr) (MD = 48.23, 95% CI: 31.96–64.49, P < .00001), 24-hour urine protein (24hpro) (MD = 0.19, 95% CI: 0.06–0.31, P = .003), uric acid (UA) (MD = 76.36, 95% CI: 12.40–140.31, P = .02), tumor necrosis factor-α (TNF-α) (MD = 10.74, 95% CI: 5.04–16.45, P = .0002), interleukin-6 (IL-6) (MD = 5.07,95% CI: 1.21–8.92, P = .01), high-sensitivity C-reactive protein (hs-CRP) (MD = 3.74, 95% CI: 0.96–6.52, P = .008) in JSB plus CT were significantly lower than those in CT. Conclusion: Combining JSB with CT has a good effect on the treatment of CRF in Chinese people. High-quality RCTs are needed to further confirm the results.